LIMN (Liminatus Pharma) Moat Score: 3/10 (As of Jul. 01, 2026)


LIMN Liminatus Pharma Inc LIMN
13 GF Score
Price $0.10
! 1 Warning Sign
View Full Analysis

What is Liminatus Pharma Moat Score?

Liminatus Pharma LIMN -8.97% 13 Moat Score is 3 as of Jul. 01, 2026. GuruFocus rates LIMN with a GF Score™ of 13/100. The stock has 1 warning sign investors should review. Among 1,400 Biotechnology companies, Liminatus Pharma ranks better than 75.5% on this metric.

Liminatus Pharma has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Liminatus Pharma has No Moat: Liminatus Pharma Inc has very weak competitive advantages. While it may possess some valuable intellectual property, it lacks market leadership, brand strength, and significant regulatory barriers, resulting in a transient competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Liminatus Pharma might have No Moat - Very weak/transient advantages.

Liminatus Pharma  (NAS:LIMN) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Liminatus Pharma Moat Score Related Terms

LIMN vs GNPX, PCSA, ELAB: Moat Score Comparison

For the Biotechnology subindustry, Liminatus Pharma's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Liminatus Pharma Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Liminatus Pharma's Moat Score distribution charts can be found below:

* The bar in red indicates where Liminatus Pharma's Moat Score falls into.


LIMN
13GF Score
Liminatus Pharma Inc LIMN
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Liminatus Pharma (LIMN) has a Moat Score of 3 as of Jul. 01, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Liminatus Pharma ranks #343 out of 1400 companies in the Biotechnology industry, placing it in the top 24.5%.
Is Liminatus Pharma's Moat Score too high?
Liminatus Pharma's current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Liminatus Pharma's value of 3 is 50% above this industry median. Based on the distribution chart, Liminatus Pharma ranks #343 out of 1400 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Liminatus Pharma has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Liminatus Pharma's Moat Score compare to GNPX and PCSA?
According to the Biotechnology industry distribution chart, Liminatus Pharma ranks #343 out of 1400 companies for Moat Score. This places Liminatus Pharma in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Liminatus Pharma's value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,400 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Liminatus Pharma's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Liminatus Pharma's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Liminatus Pharma stock overvalued right now?
Liminatus Pharma (LIMN) has a current Moat Score of 3. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Liminatus Pharma's overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Liminatus Pharma (LIMN), the current Moat Score is 3 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Liminatus Pharma Business Description

Address 12611 Hiddencreek Way, Unit C, Cerritos, CA, USA, 90703
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company engaged in developing cancer therapies and treatments. The company is developing a next generation CD47 immune checkpoint inhibitor that enables cancer cells to evade detection by the immune system. Anti-CD47 monoclonal antibodies generally induce anemia and thrombocytopenia due to their binding to red blood cells and platelets. The Liminatus CD47 mAb has shown to preferentially bind to immune cells, but not to red blood cells and platelets and does not induce hemolysis. The clinical candidate is currently in the late preclinical stage.
13GF Score

Get the complete analysis for LIMN

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.10
Price